Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
Completed
VeroScience
Phase 3
2004-07-01
Cycloset, a new quick-release oral formulation of bromocriptine mesylate, effectively reduces
blood sugar by the proposed mechanism of reversing many of the metabolic alterations
associated with insulin resistance and obesity by resetting central (hypothalamic) circadian
organization of monoamine neuronal activities.
The primary analysis of this study will test the hypothesis that the rate of all-cause severe
adverse events for those receiving usual drug therapy for diabetes management plus Cycloset
is not greater than that for usual drug therapy plus placebo by more than an acceptable
margin. While the primary purpose of this study is to establish the safety profile of
Cycloset in type 2 diabetes, any potential positive cardiovascular benefits will be evaluated
as well.
Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin
Terminated
VeroScience
Phase 3
2005-02-01
The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo
when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in
persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy
alone.
Vaginal Bromocriptine for Treatment of Adenomyosis
Completed
Mayo Clinic
Phase 1
2013-03-01
Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms
including heavy menstrual bleeding and pelvic pain. The only widely accepted treatment for
adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine, as
a therapy based on animal models of the disease and our prior clinical research to observe
any objective improvement in the extent of the disease using Magnetic Resonance Imaging
(MRI)and standard measurements for other gynecologic diseases to measure symptomatology.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
